Metabolic and Autocrine Regulation of the Mammalian Target of Rapamycin by Pancreatic β-Cells
- From the Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri
Abstract
Mammalian target of rapamycin (mTOR) is a serine and threonine protein kinase that regulates numerous cellular functions, in particular, the initiation of protein translation. mTOR-mediated phosphorylation of both the translational repressor eukaryotic initiation factor 4E binding protein-1 and p70 S6 kinase are early events that control the translation initiation process. Rapamycin, an inhibitor of mTOR, is a potent immunosuppressant due, in part, to its ability to interfere with T-cell activation at the level of translation, and it has gained a prominent role in preventing the development and progression of rejection in pancreatic islet transplant recipients. The characterization of the insulin signaling cascade that modulates mTOR in insulin-sensitive tissues has been a major focus of investigation. Recently, the ability of nutrients, in particular the branched-chain amino acid leucine, to activate mTOR independent of insulin by a process designated as nutrient signaling has been identified. The β-cell expresses components of the insulin signaling cascade and utilizes the metabolism of nutrients to affect insulin secretion. These combined transduction processes make the β-cell an unique cell to study metabolic and autocrine regulation of mTOR signaling. Our studies have described the ability of insulin and IGFs in concert with the nutrients leucine, glutamine, and glucose to modulate protein translation through mTOR in β-cells. These findings suggest that mitochondria-derived factors, ATP in particular, may be responsible for nutrient signaling. The significance of these findings is that the optimization of mitochondrial function is not only important for insulin secretion but may significantly impact the growth and proliferation of β-cells through these mTOR signaling pathways.
Footnotes
-
Address correspondence and reprint requests to Michael L. McDaniel, Department of Pathology and Immunology, Washington University School of Medicine, Box 8118, 660 South Euclid Ave., St. Louis, MO 63110. E-mail: mcdaniel{at}pathology.wustl.edu.
Received for publication 31 January 2002 and accepted in revised form 15 March 2002.
AOAA, aminooxyacetic acid; AT, aminotransferase; ±BCH, β(±) 2-aminobicyclo [2,2,1]heptane-2-carboxylic acid; BP1, binding protein 1; GDH, glutamate dehydrogenase; eIF-4E, eukaryotic initiation factor 4E; IRS, insulin receptor substrate; KATP, ATP-sensitive K+ channel; α-KG, α-ketoglutarate; α-KIC, α-ketoisocaproic acid; KRBB, Krebs-Ringer bicarbonate buffer; mTOR, mammalian target of rapamycin; OAA, oxaloacetic acid; p70s6k, p70s6 kinase; PDK1, 3-phosphoinositide-dependent kinase; PHAS, phosphorylated heat- and acid-stable protein; PHAS-I, PHAS regulated by insulin; PI-3 kinase, phosphoinositide-3 kinase; PKB, protein kinase B.
- DIABETES














